Evolution of the Average Target: AN2 Therapeutics, Inc.

Evolution of the Average Target - AN2 Therapeutics, Inc.

Evolution of the Target Price: AN2 Therapeutics, Inc.

Evolution of the Target Price - AN2 Therapeutics, Inc.

Changes in Analyst Recommendations: AN2 Therapeutics, Inc.

dca19dd2f4af297.LmQWtlft3JRXNxZm8LoF1GbWmt1XxLv0y_X20tUes98.RA1zxi3bneYfe1E1sclSgweJ2K0Fo4uTnrmCjZJsybxYBVuAPaCazhJ6ZQ~53636c99ff62468cb16adb69675279dc
07-20 Guggenheim Initiates AN2 Therapeutics at Buy With $9 Price Target MT
05-14 Leerink Partners Upgrades AN2 Therapeutics to Outperform From Market Perform, Adjusts Price Target to $9 From $1 MT
05-14 Leerink Downgrades AN2 Therapeutics to Outperform From Market Perform, Adjusts Price Target to $9 From $1 MT
18/11/24 TD Cowen Downgrades AN2 Therapeutics to Hold From Buy MT
09/08/24 Leerink Downgrades AN2 Therapeutics to Market Perform Rating With $1 Price Target MT
05/07/24 Leerink Upgrades AN2 Therapeutics to Outperform Rating With $5 Price Target MT
03/07/24 Leerink Partners Upgrades AN2 Therapeutics to Outperform From Market Perform, Price Target is $5 MT
16/05/24 Evercore ISI Adjusts Price Target on AN2 Therapeutics to $2 From $7, Maintains In-Line Rating MT
02/04/24 JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform MT
13/02/24 Leerink Partners Downgrades AN2 Therapeutics to Market Perform From Outperform, Adjusts PT to $7 From $23 MT
12/02/24 Oppenheimer Downgrades AN2 Therapeutics to Market Perform From Outperform MT
12/02/24 Evercore ISI Downgrades AN2 Therapeutics to In Line from Outperform, Adjusts PT to $7 From $25 MT
12/02/24 JMP Securities Downgrades AN2 Therapeutics to Market Perform From Market Outperform MT
04/01/24 JMP Securities Initiates AN2 Therapeutics With Market Outperform Rating, Price Target is $30 MT
14/09/23 Oppenheimer Adjusts AN2 Therapeutics Price Target to $27 From $24, Maintains Outperform Rating MT
30/03/23 Oppenheimer Adjusts AN2 Therapeutics Price Target to $24 From $20, Maintains Outperform Rating MT
10/11/22 Oppenheimer Adjusts AN2 Therapeutics Price Target to $20 From $22, Maintains Outperform Rating MT
19/04/22 Evercore ISI Initiates Coverage on AN2 Therapeutics With Outperform Rating, $25 Price Target MT
19/04/22 Oppenheimer Initiates Coverage on AN2 Therapeutics With Outperform Rating, $22 Price Target MT
19/04/22 Cowen Starts AN2 Therapeutics at Outperform MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
- - +101.34%
+40.11%
+15.84%
+7.38%
+14.09%
+17.81%
+64.61%
+29.86%
+18.88%
+58.03%
Average +36.79%
Weighted average by Cap. +27.32%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.470USD
Average target price
9.000USD
Spread / Average Target
+101.34%
High Price Target
9.000USD
Spread / Highest target
+101.34%
Low Price Target
9.000USD
Spread / Lowest Target
+101.34%

Analyst Consensus Detail

Analyst consensus - AN2 Therapeutics, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - AN2 Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ANTX Stock
  4. Consensus AN2 Therapeutics, Inc.